BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30981835)

  • 1. Synthetic T cell receptor-based lymphocytes for cancer therapy.
    Getts D; Hofmeister R; Quintás-Cardama A
    Adv Drug Deliv Rev; 2019 Feb; 141():47-54. PubMed ID: 30981835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.
    Baeuerle PA; Ding J; Patel E; Thorausch N; Horton H; Gierut J; Scarfo I; Choudhary R; Kiner O; Krishnamurthy J; Le B; Morath A; Baldeviano GC; Quinn J; Tavares P; Wei Q; Weiler S; Maus MV; Getts D; Schamel WW; Hofmeister R
    Nat Commun; 2019 May; 10(1):2087. PubMed ID: 31064990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of T cell receptor biology on the development of new T cell therapies for cancer.
    Hardy IR; Schamel WW; Baeuerle PA; Getts DR; Hofmeister R
    Immunotherapy; 2020 Jan; 12(1):89-103. PubMed ID: 31902264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
    Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
    Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
    Hiltensperger M; Krackhardt AM
    Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
    Watanabe K; Nishikawa H
    Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cancers through TCR-peptide/MHC interactions.
    He Q; Jiang X; Zhou X; Weng J
    J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
    Abken H
    Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.